or
Looking to list your PhD opportunities? Log in here.
Cancer immunotherapy holds significant promise for the treatment of a range of cancers. Immunotherapies, such Immune checkpoint inhibitors (ICIs) and oncolytic viruses (OVs), have been assessed in clinical trials against a range of solid tumours; however, positive therapeutic responses are often limited due to immune evasion strategies that exist within the tumour. For example, cyclooxygenase (COX2)-mediated production of prostaglandin E2 (PGE2) modulates a range of tumour promoting phenomena including tumour migration and the induction of an immunosuppressive tumour microenvironment. Therefore, intensive research efforts are being made to identify combination therapies that can potentiate the response to immunotherapies. Importantly, our preliminary work has identified eicosapentaenoic acid (EPA) as a promising agent to potentiate both ICI and OVs in solid tumours. Specifically, pre-clinical and clinical evidence has demonstrated that EPA has anti-inflammatory and anti-cancer activity (1-2) and although EPA mechanisms of action are multifactorial, EPA-driven reduction of PGE2 production by COX-2 plays a key role in its anti-cancer activity.
One significant difficulty in the pre-clinical assessment of anti-cancer immunotherapy combinations is that standard in vitro models do not replicate the complexity of the tumour microenvironment, whilst animal models are time consuming, expensive and not always available. Our group has recently developed multi-cellular tumour spheroids (MCTS) in an attempt to model the tumour microenvironment in vitro. The aim of this PhD project is to expand the range, and complexity of MCTS, developing MCTS which incorporate cancer cells, fibroblasts, monocytes, and PBMC for a range tumour types. More complex MCTS will better recapitulate the tumour microenvironment, allowing us to test the anti-cancer activity of immunotherapy-based treatment combinations, and investigate interactions between cancer cells, fibroblasts and immune cells in 3D models. Importantly, during this project MCTS will also be compared with patient samples to validate their relevance as an alternative in vitro cancer model.
The establishment of MCTS will: (i) allow screening for efficacious drug combinations, including EPA with immunotherapies; (ii) enable characterisation of immunosuppressive signalling networks; and (iii) facilitate the identification of potential biomarkers of response. Ultimately this work aims to support the development of novel clinical strategies which will potentiate immunotherapies, including EPA, ICIs and OVs (3).
Techniques associated with this project:
This project will utilise standard cell culture techniques for established cell lines and primary patient samples. The student will grow and treat cells in 3D MCTS, collect conditioned medium to assess soluble mediators by ELISA, and characterise cellular components using immunohistochemistry and flow cytometry. Gene expression analysis will also be performed using real-time RT-PCR.
This project is part of the International PhD Academy: Medical Research
Eligibility:
You should hold a first degree equivalent to at least a UK upper second class honours degree in a relevant subject.
Candidates whose first language is not English must provide evidence that their English language is sufficient to meet the specific demands of their study. The Faculty of Medicine and Health minimum requirements are:
How to apply:
Applications can be made at any time. To apply for this project applicants should complete an online application form and attach the following documentation to support their application.
To help us identify that you are applying for this project please ensure you provide the following information on your application form;
Any queries regarding the application process should be directed to [Email Address Removed]
Based on your current searches we recommend the following search filters.
Check out our other PhDs in Leeds, United Kingdom
Start a New search with our database of over 4,000 PhDs
Based on your current search criteria we thought you might be interested in these.
Modelling the Impact of Diagnostic Pathways in Cancer and Cardiovascular Disease - University of Swansea (part of Health Data Research UK’s Big Data for Complex Disease Driver Programme)
Health Data Research UK
Endosomal Sorting Complex Required for Transport (ESCRT): Investigation of the role in acquired drug resistance in colon cancer
University of Bradford
CRUK Black Leaders in Cancer Non-Clinical PhD Scholarship: The ageing tumour microenvironment in ER+ breast cancer - identifying age-associated regulators of cytotoxic T-cell infiltration and activity
The University of Manchester